Effect of vitamin D deficiency correction on serum Fibroblast growth factor 23 level

Effect of vitamin D deficiency correction on serum Fibroblast growth factor 23 level in vitamin D deficient patients and comparision with vitamin D deficient patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138707171312N1

Enrollment

120

Registered

2017-05-16

Start date

2015-12-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin D deficiency. Vitamin D deficiency

Interventions

Intervention 1: In case group patients with vitamin D deficiency were treated with 50000 unit vitamin D on fridays for 3 months and at the end of 3 months level of Calcium , Phosphorous ,Fibroblast gr

Treatment - Drugs

Placebo

In case group patients with vitamin D deficiency were treated with 50000 unit vitamin D on fridays for 3 months and at the end of 3 months level of Calcium , Phosphorous ,Fibroblast growth factor 23,

In control group patients were treated with placebo( olive oil capsule) on fridays for 3 months and at the end of 3 months, level of Calcium , Phosphorous, fibroblast growth factor 23, parathormon ,

Eligibility

Sex/Gender

All

Age

15 Years to 90 Years

Inclusion criteria

Inclusion criteria: Vitamin D deficient patients (serum vitamin D level under 20 ng/ml) in both sexes and in range 15-90 years old were included in this study. patients who had underlying diseases such as osteomalacia, renal failure,hyperparathyroidism; hypoparathyroidism; osteoporesis; hereditary bone disease such as autosomal dominant hypophosphatemic rickets; autosomal recessive hypophosphatemic rickets, vitamin D resistant rickets; vitamin D dependent rickets; X- linked hypophosphatemia autosomal recessive hypophosphatemia and fibrous dysplasia; recent consumption of calcium supplement; concurrent use of drugs that interfere with vitamin D such as iron supplement; Alluminum and Magnesium admixture such as anti acid drugs; proton pump inhibitors (PPI) like Omeprazole or pantoprazole; bile acid binding resins like cholestyramine; cardiac glycosides such as Digoxin; Danazole; Multi vitamin and minerals; Sucralfate;Orlistat;Thiazide diuretic; alcohol consumption; consumption of other analogs of vitamin D; Herbal drugs; use of Olive; pregnant and lactating women were exclude from the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FGF23. Timepoint: Basal and 3 month after. Method of measurement: blood sample.	—

Secondary

Measure	Time frame
Calcium. Timepoint: Basal and 3 month after. Method of measurement: blood sample.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactForugh Saki

Shiraz University of Medical Science

Forughs@yahoo.com+98 917 712 7122

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026